Chemotherapy plus bevacizumab vs chemoimmunotherapy for metastatic colorectal cancer: Real-world analysis
1. 系统已在2025-12-01 12:29:48对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
Z Gao, ZF Zhou, XY Wang, T Song…
World Journal of …, 2025
pmc.ncbi.nlm.nih.gov
BACKGROUND Clinical trial evidence points to chemotherapy's potential in augmenting the effects of immunotherapy. AIM To assess the effectiveness of first-line chemoimmunotherapy (CIT) for microsatellite stable (MSS) metastatic colorectal cancer (mCRC) verses standard-of-care (SOC; 5-fluorouracil/leucovorin/oxaliplatin/bevacizumab). METHODS This was a multicenter retrospective cohort study conducted in Peking University First Hospital and Jilin Cancer Hospital. Patients with MSS mCRC who had received first-line treatment were …
